• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300858.SZ
Share

Beijing Scitop Bio-tech Co., Ltd. Stocks

CN¥ 14.93Last Updated 15.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 568.52M

CN¥ 14.93
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Scitop Bio-tech Co., Ltd. operates in China, specializing in the research, production, and sale of probiotic lactic acid bacteria and their related derivatives. The company's product range also encompasses complex food additives, consumer-grade probiotic items, and specialized microecological preparations for both animal and plant applications. These diverse solutions are utilized across various industries, including food processing, healthcare, livestock farming, and crop cultivation. Founded in 2003, Beijing serves as the company's main operational hub.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300858.SZ is 17.7 and suggests 22.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 07:30

UBS recommends buying SpaceX shares ahead of a new rocket test. The shares have fallen 33% from their peak.

16.07.2026 03:25

Apple Is on the Hunt for AI Chip Makers — The Information

16.07.2026 02:05

JPMorgan, BlackRock, and Goldman plan to tokenize stocks and government bonds

16.07.2026 01:11

OpenAI has unveiled its first gadget—a keyboard for controlling AI agents

16.07.2026 00:42

"The rumors are completely false": Lucid denies risk of bankruptcy, shares soar 30%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026